Citations

Clear

813 citation(s) found for "He, Helen".

A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).
Chmura, Steven J. , Allred, Jacob B., Salama, Joseph K. , Al‐Hallaq, Hania , Hsu, Charles C., Kozloff, M., Luke, Jason J. , Yom, Sue S. , Münster, Pamela N. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS9599-TPS9599

10.1200/jco.2018.36.15_suppl.tps9599 Get It

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
Ross, Helen J. , Kozono, David , Urbanic, James J., DuFrane, Carter, Bāra, Ilze, Gandhi, Mayank , Schulze, Katja , Brockman, Jane Michelle, Wang, Xiaofei F., Stinchcombe, Tom, Kozono, David E , Williams, Terence M. , Vokes, Everett E. , Stinchcombe, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8585-TPS8585

10.1200/jco.2018.36.15_suppl.tps8585 Get It

Polygenic risk score for breast cancer in high-risk women.
Black, Mary Helen , Li, Shuwei , LaDuca, Holly , Chen, Jefferey, Hoiness, Robert, Gutierrez, Stephanie, Lu, Hsiao‐Mei, Dolinsky, Jill S. , Xu, Jianfeng , Vachon, Celine M. , Davis, Brigette Tippin, Vachon, Celine M. , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1508-1508

10.1200/jco.2018.36.15_suppl.1508 Get It

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Konstantinopoulos, Panagiotis A. , Waggoner, Steven , Vidal, Gregory A. , Mita, Monica , Holloway, Robert W. , Le, Linda Van, Sachdev, Jasgit C. , Chapman‐Davis, Eloise , Colón‐Otero, Gerardo , Penson, Richard T. , Matulonis, Ursula A. , Kim, Young B., Dezube, Bruce J., Wang, Jing Y., Buerstatte, Nathan, Arora, Sujata, Münster, Pamela N. , Munster, Pamela , Konstantinopoulos, Panagiotis A , Fleming, Gini F. , Moore, Kathleen N. , Swisher, Elizabeth M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 106-106

10.1200/jco.2018.36.15_suppl.106 Get It

INPP5a expression as a prognostic marker in cutaneous squamous cell carcinoma (cSCC).
Liang, Helen J, DiCaudo, David J. , Schmidt, Jessica, Pittelkow, Mark R. , Sekulić, Aleksandar , Mangold, Aaron R. , Mangold, A R , Liang, Helen J

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21567-e21567

10.1200/jco.2018.36.15_suppl.e21567 Get It

A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
Foster, Nathan R. , Zoroufy, Alexander J., Souza, Jonas A. de, Jelinek, Michael J. , Schwartz, Gary K. , Münster, Pamela N. , Seiwert, Tanguy Y. , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 6031-6031

10.1200/jco.2018.36.15_suppl.6031 Get It

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.
Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission
Auvin, Stéphane , Donald, Kirsten A. , Hartmann, Hans , Valente, Kette D. , Bogaert, Patrick Van , Cross, J. Helen , Ōsawa, Makiko, Kanemura, Hideaki , Aihara, Masao, Guerreiro, Marilisa M. , Vinayan, Kollencheri Puthenveettil , Smith, Mary Lou , Carmant, Lionel, Kerr, Michael , Dunn, David , Wilmshurst, Jo M. , Berl, Madison , Kanemura, Hideaki , Wilmshurst, Jo M , Auvin, Stéphane , Cross, Helen J , Valente, Kette , Wirrell, Elaine , Berl, Madison M. , Samia, Pauline , Hermann, Bruce P.

Mayo Clinic

Epilepsia | September 4, 2018 | Volume: 59 | Issue: 10 | Pages: 1867-1880

10.1111/epi.14549 | PMID 30178479 Get It

SummaryAttention‐deficit/hyperactivity disorder (ADHD) is a common and challenging comorbidity affecting many children with epilepsy. A working group under the International League Against Epilepsy (ILAE) Pediatric Commission identified key questions on the identification and management of ADHD in children with epilepsy. Systematic reviews of the evidence to support approaches to these questions were collated and graded using criteria from the American Academy of Neurology Practice Parameter. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) requirements were followed, with PROSPERO registration (CRD42018094617). No increased risk of ADHD in boys with epilepsy compared to girls with epilepsy was found (Level A). Valproate use in pregnancy is associated with inattentiveness and hyperactivity in offspring (1 class I study), and children with intellectual and developmental disabilities are at increased risk of ADHD (Level A). Impact of early seizure onset on development of ADHD was unclear (Level U), but more evident with poor seizure control (Level B). ADHD screening should be performed from 6 years of age, or at diagnosis, and repeated annually (Level U) and reevaluated after change of antiepileptic drug (AED) (Level U). Diagnosis should involve health practitioners with expert training in ADHD (Level U). Use of the Strength and Difficulties Questionnaire screening tool is supported (Level B). Formal cognitive testing is strongly recommended in children with epilepsy who are struggling at school (Level U). Behavioral problems are more likely with polytherapy than monotherapy (Level C). Valproate can exacerbate attentional issues in children with childhood absence epilepsy (Level A). Methylphenidate is tolerated and effective in children with epilepsy (Level B). Limited evidence supports that atomoxetine is tolerated (Level C). Multidisciplinary involvement in transition and adult ADHD clinics is essential (Level U). In conclusion, although recommendations could be proposed for some of the study questions, this systematic review highlighted the need for more comprehensive and targeted large‐population prospective studies.
Age‐specific genome‐wide association study in glioblastoma identifies increased proportion of ‘lower grade glioma’‐like features associated with younger age
Ostrom, Quinn T. , Kinnersley, Ben , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Eckel‐Passow, Jeanette E. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Houlston, Richard S. , Jenkins, Robert B. , Wrensch, Margaret , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Armstrong, Georgina , Chen, Yanwen , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Rubin, Joshua B , Chanock, Stephen Jacob , Yeager, Meredith , Ostrom, Quinn T

Mayo Clinic

International Journal of Cancer | August 29, 2018 | Volume: 143 | Issue: 10 | Pages: 2359-2366

10.1002/ijc.31759 | PMID 30152087 Get It

Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age‐at‐diagnosis is significantly associated with improved prognosis. While the relationship between candidate GBM risk SNPs and age‐at‐diagnosis has been explored, genome‐wide association studies (GWAS) have not previously been stratified by age. Potential age‐specific genetic effects were assessed in autosomal SNPs for GBM patients using data from four previous GWAS. Using age distribution tertiles (18–53, 54–64, 65+) datasets were analyzed using age‐stratified logistic regression to generate p values, odds ratios (OR), and 95% confidence intervals (95%CI), and then combined using meta‐analysis. There were 4,512 total GBM cases, and 10,582 controls used for analysis. Significant associations were detected at two previously identified SNPs in 7p11.2 (rs723527 [p54–63 = 1.50x10−9, OR54–63 = 1.28, 95%CI54–63 = 1.18–1.39; p64+ = 2.14x10−11, OR64+ = 1.32, 95%CI64+ = 1.21–1.43] and rs11979158 [p54–63 = 6.13x10−8, OR54–63 = 1.35, 95%CI54–63 = 1.21–1.50; p64+ = 2.18x10−10, OR64+ = 1.42, 95%CI64+ = 1.27–1.58]) but only in persons >54. There was also a significant association at the previously identified lower grade glioma (LGG) risk locus at 8q24.21 (rs55705857) in persons ages 18–53 (p18–53 = 9.30 × 10−11, OR18–53 = 1.76, 95%CI18–53 = 1.49–2.10). Within The Cancer Genome Atlas (TCGA) there was higher prevalence of ‘LGG’‐like tumor characteristics in GBM samples in those 18–53, with IDH1/2 mutation frequency of 15%, as compared to 2.1% [54–63] and 0.8% [64+] (p = 0.0005). Age‐specific differences in cancer susceptibility can provide important clues to etiology. The association of a SNP known to confer risk for IDH1/2 mutant glioma and higher prevalence of IDH1/2 mutation within younger individuals 18–53 suggests that more younger individuals may present initially with ‘secondary glioblastoma.’
Sex-specific gene and pathway modeling of inherited glioma risk
Ostrom, Quinn T. , COLEMAN, WARREN, Lathia, Justin D. , Liao, Peter, Wrensch, Margaret , Eckel‐Passow, Jeanette E. , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Houlston, Richard S. , Jenkins, Robert B. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Bracci, Paige M. , Molinaro, Annette M. , Pezmecki, M, Prados, Michael D. , Smirnov, Ivan, Wiemels, Joseph L. , Zheng, Shichun, Visvanathan, Kala , Stevens, Victoria L. , Henriksson, Roger , Feychting, Maria , Ahlbom, Anders , Milne, Graham G Giles Roger, McKean‐Cowdin, Roberta , Stampfer, Meir J. , Ruder, Avima M., Hallmans, Göran , Gaziano, J. Michael , Sesso, Howard D. , Purdue, Mark P. , Peters, Ulrike , Buring, Julie E. , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Visvanathan, Kala , Coleman, Warren, Huang, William Y. C. , Rubin, Joshua B , Berens, Michael E. , Speyer, Gil , Armstrong, Georgina , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Chanock, Stephen Jacob , Yeager, Meredith , Berger, Mitchel S. , Chang, Stephen , Clarke, Jennifer , Molinaro, Annette M. , Perry, Arie , Tihan, Tarık , Walsh, Kyle M. , Freeman, Laura E. Beane , Koutros, Stella , Albanes, Demetrius , Michaud, Dominique S. , Marchand, Loı̈c Le , Carreón, Tania , Zeleniuch‐Jacquotte, Anne , White, Emily , Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology | August 8, 2018 | Volume: 21 | Issue: 1 | Pages: 71-82

10.1093/neuonc/noy135 | PMID 30124908 Get It